Study of FCN-159 for NF2 nerve sheath tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an oral drug called FCN-159 for people with NF2-related nerve sheath tumors that cannot be fully removed by surgery or have come back after surgery. It aims to see if the drug can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 years or older.
- You must have a confirmed diagnosis of NF2 or a related nerve sheath tumor.
- Your tumor either wasn't fully removed by surgery, came back after surgery, or your doctor says you need systemic therapy.
- You must have at least one tumor that can be measured on scans.
- You must be in good enough health to perform daily activities (Karnofsky score of 70 or higher).
- You cannot have had certain prior treatments like MEK inhibitors (e.g., selumetinib) or chemotherapy within a set time before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy that is injected directly into tumors caused by NF2. It aims to help people whose tumors have not responded to standard treatments.
This trial tests a combination of two investigational drugs for people with NF2-related tumors. The drugs target specific pathways to help shrink or slow growth of vestibular schwannomas and meningiomas.
This study is looking at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It first tracks the natural course of the disease and may later test experimental drugs to help shrink or control tumors.
This trial tests a drug called selumetinib (a pill) for people with NF2-related schwannomatosis, a condition that causes non-cancerous tumors to grow on nerves, especially near the ears. The goal is to see if the drug can shrink or stabilize these tumors and protect hearing.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
This trial tests a new medicine called PRG-N-01 for people with neurofibromatosis type 2 (NF2), a condition that causes tumors on nerves. The study aims to find the best dose and see if the medicine can shrink tumors or improve symptoms like hearing loss or pain, especially for those who cannot have surgery.
Hear when a new Nerve Sheath Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.